Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Phase 2 Completed 39 enrolled H. Lee Moffitt Cancer Center and Research Institute Pfizer · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to decide if a medicine that slows growth of new blood vessels can be give after the embolization procedure to prevent or delay new growth of blood vessels to tumors.

Timeline

Start: 2006-11
Primary completion: 2012-02
Completion: 2012-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	37.5 mg	Oral

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization

Summary

Timeline

Drugs

Indications